Literature DB >> 25391404

Australian vaccine preventable disease epidemiological review series: pertussis, 2006-2012.

Alexis Pillsbury1, Helen E Quinn2, Peter B McIntyre2.   

Abstract

Despite pertussis vaccine being available since the 1940s and immunisation programs using combined diphtheria-tetanus-pertussis vaccine since the mid-1950s, pertussis has been the most commonly notified vaccine preventable disease in Australia over the past 20 years. Pertussis notification and hospitalisation data have been available nationally since 1993, and provide different perspectives for understanding epidemiological trends. This report follows on from a previous review of Australian pertussis epidemiology from 1995-2005 and summarises routinely collected notification, hospitalisation and mortality data for 2006-2012. During the latter 7-year period, which incorporated epidemics in all jurisdictions, and in which acellular vaccines (as opposed to whole cell vaccines) were used exclusively, the average annual notification rate was more than 2.8 times that of the previous decade. In contrast, hospitalisation and mortality rates remained similar. The pattern of age-specific notification rates changed substantially, with cases aged 15 years or over representing 93% of total cases in 2006, but only 58% by 2012; the steepest increases were seen in children 2-4 and 6-9 years of age. In South Australia, where acellular vaccines were introduced into the primary schedule 2 years earlier than in other jurisdictions except the Northern Territory, a peak in notifications among those aged 5-9 and 10-12 years was observed earlier. Likely contributors to both the overall increase in notifications and changes in age distribution include increased diagnostic testing and more rapid waning of effectiveness following vaccination with acellular compared with whole cell vaccines, exacerbated by cessation of the 18-month dose in the National Immunisation Program from 2003. This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or by email to copyright@health.gov.au.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25391404

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  17 in total

1.  Baseline incidence of adverse birth outcomes and infant influenza and pertussis hospitalisations prior to the introduction of influenza and pertussis vaccination in pregnancy: a data linkage study of 78 382 mother-infant pairs, Northern Territory, Australia, 1994-2015.

Authors:  L McHugh; R M Andrews; B Leckning; T Snelling; M J Binks
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

Review 2.  What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing.

Authors:  Dimitri A Diavatopoulos; Kathryn Margaret Edwards
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

Review 3.  Vaccines in pregnancy: The dual benefit for pregnant women and infants.

Authors:  H Marshall; M McMillan; R M Andrews; K Macartney; K Edwards
Journal:  Hum Vaccin Immunother       Date:  2016-04-02       Impact factor: 3.452

4.  Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness.

Authors:  Ousseny Zerbo; Bruce Fireman; Nicola P Klein
Journal:  Expert Rev Vaccines       Date:  2021-10-08       Impact factor: 5.683

Review 5.  Immunization During Pregnancy: Impact on the Infant.

Authors:  Kirsten P Perrett; Terry M Nolan
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

6.  Pertussis epidemiology prior to the introduction of a maternal vaccination program, Queensland Australia.

Authors:  L McHugh; K A Viney; R M Andrews; S B Lambert
Journal:  Epidemiol Infect       Date:  2017-12-06       Impact factor: 4.434

7.  Epidemiology of pertussis-related paediatric intensive care unit (ICU) admissions in Australia, 1997-2013: an observational study.

Authors:  Marlena C Kaczmarek; Robert S Ware; Julie A McEniery; Mark G Coulthard; Stephen B Lambert
Journal:  BMJ Open       Date:  2016-04-06       Impact factor: 2.692

Review 8.  Lessons learnt from the implementation of maternal immunization programs in England.

Authors:  G Amirthalingam; L Letley; H Campbell; D Green; J Yarwood; M Ramsay
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

9.  Annual vaccine-preventable disease report for New South Wales, Australia, 2014.

Authors:  Nathan Saul; Robin Gilmour; Paula Spokes
Journal:  Western Pac Surveill Response J       Date:  2017-06-26

10.  Under-reporting of pertussis in Ontario: A Canadian Immunization Research Network (CIRN) study using capture-recapture.

Authors:  Natasha S Crowcroft; Caitlin Johnson; Cynthia Chen; Ye Li; Alex Marchand-Austin; Shelly Bolotin; Kevin Schwartz; Shelley L Deeks; Frances Jamieson; Steven Drews; Margaret L Russell; Lawrence W Svenson; Kimberley Simmonds; Salaheddin M Mahmud; Jeffrey C Kwong
Journal:  PLoS One       Date:  2018-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.